MGTA - Magenta Therapeutics down 50% on acute myeloid leukemia dose escalation trial
- Magenta Therapeutics ( NASDAQ: MGTA ) has dropped 50% in Tuesday morning trading after it stopped dosing in a cohort of an acute myeloid leukemia candidate dose escalation trial due to toxicities .
- Two of the three participants in that cohort experienced dose-limiting toxicities.
- The company stopped dosing participants at the 0.13 mg/kg dose level in a phase 1/2 trial for MGTA-117. Instead, it will dose additional patients at the 0.08 mg/kg level.
- Earlier in December, Magenta ( MGTA ) presented positive proof-of-concept data on MGTA-117 .
For further details see:
Magenta Therapeutics down 50% on acute myeloid leukemia dose escalation trial